Effects Of Caffeine On Cognitive Performance

Caffeine Clinical Trial

Official title:

Effects Of Different Doses Of Caffeine On Cognitive Performance In Healthy Physically Active Individuals

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05995314
• Other study ID #: CAF_MR_2023
• Status: Completed
• Phase: N/A
• Start date: August 7, 2023
• Est. completion date: September 4, 2023

Study information

• Verified date: September 2023
• Source: University of Castilla-La Mancha
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Caffeine is a potent central nervous system stimulant that increases the activity in the prefrontal cortex and can improve cognitive skills. An improvement in these cognitive skills can lead to further benefits in athletic performance. Therefore, it is necessary to clarify the dose-response of caffeine on cognitive performance.The aim of this research will be to determine the effects of different doses of caffeine on sport-related cognitive aspects.

Description:

The investigators will require healthy, physically active young adults to complete three trials under the conditions: a) placebo, b) 3 mg/kg, or c) 6 mg/kg body mass of caffeine. In each trial, different cognitive abilities will be assessed using the following test batteries: reaction time (DynavisionTM D2), anticipation (Bassin Anticipation Timer), sustained attention (Go/No-Go and Eriksen Flanker Test) and memory tests. In addition, side effects and the perceived sensation index will be recorded 24 h after each test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 4, 2023
• Est. primary completion date: September 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Physically active individuals ( >150 min/week moderate physical activity or >75 min/week vigorous physical activity)
• Individuals without serious and undiagnosed health problems.

Exclusion Criteria:

• Individuals with color blindness.
• Regular caffeine consumers (>3 cups of coffee/day).

Related Conditions & MeSH terms

• Caffeine

Intervention

Dietary Supplement:
• PLACEBO
3 mg/kg of cellulose (0 mg/kg of caffeine)
• 3 mg/kg of caffeine
Ingestion of 3 mg/kg of body mass of caffeine
• 6 mg/kg of caffeine
Ingestion of 6 mg/kg of body mass of caffeine

Locations

Country	Name	City	State
Spain	Performance and Sport Rehabilitation Laboratory	Toledo

Sponsors (1)

Lead Sponsor	Collaborator
University of Castilla-La Mancha

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reaction Time	Reaction time (in seconds) shall be assessed with the Dynavision™ D2 Visomotor Device using the "Reaction Time Test". In this test the fastest visual, motor and physical reaction time will be measured.	10 minutes
Primary	Anticipation	Visual acuity related to hand-eye coordination and anticipation will be assessed using the Bassin Anticipation Timer instrument. The best anticipation time (in seconds) of each condition (5, 10 and 15 mph) will be taken.	5 minutes
Primary	Sustained attention	The ability of maintaining the attention and inhibiting an appropriate response will be measured by "Go/No-Go Test" [fastest, slowest, and average response time (in seconds), and successful attempts (percentage; %)] and "Eriksen Flanker Test" [congruent and incongruent reaction time (in seconds)].	10 minutes
Primary	Memory	To study the modulation of memory storage processes, three 20-item word lists were created. Each word in the list will be presented for 5 s. This will be followed by a 100 s memory consolidation interval, after which there will be a 120 s period in which as many words as the participants can remember will be written down (First time). After 15 min, participants will perform a recall task (Second time) in which they will have to rewrite all the words they remember at that time.	20 minutes